NO954072L - Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler - Google Patents

Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler

Info

Publication number
NO954072L
NO954072L NO954072A NO954072A NO954072L NO 954072 L NO954072 L NO 954072L NO 954072 A NO954072 A NO 954072A NO 954072 A NO954072 A NO 954072A NO 954072 L NO954072 L NO 954072L
Authority
NO
Norway
Prior art keywords
alkyl
blend
hydrogen
antitumor agents
group
Prior art date
Application number
NO954072A
Other languages
English (en)
Other versions
NO954072D0 (no
Inventor
Angelo Bedeschi
Franco Zarini
Walter Cabri
Ilaria Candiani
Sergio Penco
Laura Capolongo
Original Assignee
Pharmacia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Spa filed Critical Pharmacia Spa
Publication of NO954072D0 publication Critical patent/NO954072D0/no
Publication of NO954072L publication Critical patent/NO954072L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Nye camptoteclnderivat av formel (I) B fl. hvor B er en gruppe B' eller B" *'^R' l B1 M ° (y) B" hvor hver av (x) og (y) er en enkelt- eller dobbeltblnding, R! og R2 er hver uavhengig hydrogen, q-C^alkyl, Cg-C7-cykloalkyl, fenyl-C^-alkyl eller en usubetltuert eller substituert fenylrlng, R3 og R4 er (a) hver uavhengig, substltuenter som har samte betydning son RI og Rgt eller (b) l kombinasjon sanmen med nltrogenatomet til hvilket de er bundet danner en 3-7-leddet mettet, usubstituert eller ! substituert heteranonocykllsk ring, son ytterligere kan Inneholde et annet heteroatoa valgt fra nitrogen, oksygen og svovel, og ! A" er et farmasøytisk akseptabelt anion av en farmasøytisk akseptabel uorganisk eller organisk syre, forutsatt at (i) når (i) er en dobbeltblndlng, så er (y) en enkeltblndlng og når (y) er en dobbeltblndlng, så er (T) en enkelt- blndlng, og ! (11) når B er en gruppe B', så er en av R2, R3 og fy fraværende; R£ er hydrogen eller Ci-C^-alkyl; X er hydrogen, q-^-alkyl, q-Ct-alkoksy, Ci-Cft-acyloksy, Cs-Cy-cykloalkyl, Cg^-cykloalkoksy, benzoyloksy, amino, hydroksy, nltro, et halogenatom eller en metylendioksygruppe bundet til stilling 10 og 11 i molekylet; og de farmasøy- tisk akseptable saltene derav. Disse caqptoteclnderlvatene er nyttige l terapi som antitumonnidler.
NO954072A 1994-02-16 1995-10-13 Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler NO954072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402934A GB9402934D0 (en) 1994-02-16 1994-02-16 Camptothecin derivatives and process for their preparation
PCT/EP1995/000393 WO1995022549A1 (en) 1994-02-16 1995-02-03 Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents

Publications (2)

Publication Number Publication Date
NO954072D0 NO954072D0 (no) 1995-10-13
NO954072L true NO954072L (no) 1995-12-11

Family

ID=10750430

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954072A NO954072L (no) 1994-02-16 1995-10-13 Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler

Country Status (20)

Country Link
US (2) US5602141A (no)
EP (1) EP0694035B1 (no)
JP (1) JPH08509244A (no)
KR (1) KR960701878A (no)
CN (1) CN1123548A (no)
AT (1) ATE220681T1 (no)
AU (1) AU681941B2 (no)
CA (1) CA2158855C (no)
DE (1) DE69527400T2 (no)
ES (1) ES2180625T3 (no)
FI (1) FI954898A0 (no)
GB (1) GB9402934D0 (no)
HU (1) HUT73423A (no)
IL (1) IL112622A (no)
MX (1) MX9504287A (no)
NO (1) NO954072L (no)
NZ (1) NZ279813A (no)
PL (1) PL311122A1 (no)
WO (1) WO1995022549A1 (no)
ZA (1) ZA951227B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
GB9410388D0 (en) * 1994-05-24 1994-07-13 Erba Carlo Spa Method for the preparation of 9-amino camptothecin
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
GB9601779D0 (en) * 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
GB9702807D0 (en) 1997-02-12 1997-04-02 Pharmacia & Upjohn Spa Alkynyl-substituted camptothecins and process for their preparation
GB9715821D0 (en) * 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ATE398131T1 (de) * 2001-11-30 2008-07-15 Chugai Pharmaceutical Co Ltd Kondensierte camptothecine als antitumormittel
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
UA88008C2 (en) 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP5126900B2 (ja) * 2009-02-24 2013-01-23 株式会社渡辺オイスター研究所 カキ肉エキス顆粒の製造方法。
CN101555250B (zh) * 2009-05-19 2011-05-18 重庆泰濠制药有限公司 盐酸拓扑替康的制备方法
BR112023024433A2 (pt) * 2021-05-27 2024-02-20 Zymeworks Bc Inc Análogos, conjugados e métodos de uso de camptotecina
MX2024003496A (es) 2021-10-15 2024-04-05 Kunshan Xinyunda Biotech Co Ltd Composicion que contiene un farmaco antitumoral, metodo de preparacion y uso de este.
IL315393A (en) * 2022-03-25 2024-11-01 Zymeworks Bc Inc Antibody preparations for drugs targeting alpha acid receptor and methods of use
TW202421137A (zh) * 2022-10-19 2024-06-01 加拿大商酵活英屬哥倫比亞有限公司 靶向ＮａＰｉ２ｂ之抗體—藥物結合物及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
WO1991004260A2 (en) * 1989-09-15 1991-04-04 Research Triangle Institute 10,11-methylenedioxy-20(rs)-camptothecin and 10,11-methylenedioxy-20(s)-camptothecin analogs
DK0418099T3 (da) * 1989-09-15 2002-04-02 Res Triangle Inst Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
JP2848958B2 (ja) * 1990-09-28 1999-01-20 スミスクライン・ビーチャム・コーポレイション 水溶性カンプトテシン類似体、方法および手段
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation

Also Published As

Publication number Publication date
DE69527400T2 (de) 2003-03-06
CN1123548A (zh) 1996-05-29
CA2158855C (en) 2006-01-31
CA2158855A1 (en) 1995-08-24
HUT73423A (en) 1996-07-29
PL311122A1 (en) 1996-02-05
IL112622A (en) 1997-09-30
FI954898A7 (fi) 1995-10-13
US5801167A (en) 1998-09-01
ZA951227B (en) 1996-01-19
NO954072D0 (no) 1995-10-13
EP0694035B1 (en) 2002-07-17
AU681941B2 (en) 1997-09-11
GB9402934D0 (en) 1994-04-06
FI954898A0 (fi) 1995-10-13
KR960701878A (ko) 1996-03-28
EP0694035A1 (en) 1996-01-31
MX9504287A (es) 1997-05-31
AU1705695A (en) 1995-09-04
IL112622A0 (en) 1995-05-26
US5602141A (en) 1997-02-11
HU9503273D0 (en) 1996-01-29
WO1995022549A1 (en) 1995-08-24
JPH08509244A (ja) 1996-10-01
NZ279813A (en) 1996-10-28
ES2180625T3 (es) 2003-02-16
DE69527400D1 (de) 2002-08-22
ATE220681T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
MX9504287A (es) Derivados de camptotecina y proceso para su preparacion.
TR200100698T2 (tr) 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
BR0213025A (pt) Compostos de espiro-hidantoìna úteis como agentes antiinflamatórios
TR199800720T2 (xx) Farnesil transferaz inhibe eden 2-kinolon t�revleri.
CR8755A (es) Derivado de quinolina fusionada y uso del mismo
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
AR035548A1 (es) Compuestos organicos
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
MY105402A (en) 17-beta-substituted-4-aza-5alpha-androstan-3-one derivatives and process for their preparation.
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
NO983970D0 (no) Tricykliske forbindelser, deres fremstilling og anvendelse
MY114679A (en) Aroyl-piperidine derivatives
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
AR019788A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso y procedimientos para prepararlos
DK0388948T3 (da) Acryloylsubstituerede pyrrolderivater
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO943895L (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
NO964698D0 (no) Bicykliske aminderivater som inhibitorer av nitrogenoksid-syntetase
DK534381A (da) Fremgangsmaade til fremstilling af 2-oxoazetidinderivater
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
ES2012648A6 (es) Procedimiento para la preparacion de nuevos derivados de 1,4-benzoxazina y 1,4-benzotiazina.
WO2002094770A3 (en) Aminoalcohol derivatives
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem